Oncode is the independent institute dedicated to outsmarting cancer and impacting lives.
Carl Figdor and Michiel Vermeulen participate in the Oncode Institute for Radboudumc and Radboud University, respectively.
Research programmeDespite enormous progress in our understanding of cancer, the chance of long-term survival remains small for many patients, particularly those with metastatic disease. Oncode will address this unmet clinical need through an innovative basic research programme. True innovation in the treatment of cancer relies on new insights into the basic mechanisms of oncogenesis, which in turn depend heavily on technological innovation. Oncode research will be guided by a number of key questions that need to be resolved to extend life expectancy and improve quality of life for cancer patients.
Principal scientific questionsThe key issues in cancer research today are summed up in our principal scientific questions:
- Can we define new and better targets for therapy on the basis of detailed analyses of tumours, tumour-derived cell lines and organoids, and xenografts?
- What is the basis for tumour heterogeneity, and how can we harness this knowledge to refine cancer therapy?
- What role does the cell of origin play in a tumour’s characteristics and responsiveness to therapy?
- How do cancer cells avoid host immune attack, and how can we stop them from doing so?
- How do non-mutated background genes influence tumour formation and response to therapy?
- Can we develop novel models to predict therapy response?
- How can we prevent metastatic disease?
Scientific themesOn the basis of these questions, Oncode’s founding scientists have identified six scientific themes that constitute the basis of the integrated research strategy:
- Development of novel technologies
- Understanding the critical drivers of tumour growth and the causes of resistance
- Analysis of network perturbations in tumours and tumour-host interactions
- Causes and consequences of genetic instability
- Identification of critical drug combinations and biomarkers for personalized cancer treatments
- Mobilizing immune defence
Read more on the Oncode website.
Related news items
Working energetically from home3 December 2020
By now, you may have gotten used to it: working from home. The page ‘Working energetically from home‘ offers you tips to help you work from home better, from setting up a good workspace to working more effectively and maintaining a good work-life balance.read more
Controlled Human Malaria Infection Induces Long-Term Functional Changes in Monocytes3 December 2020
Robert Sauerwein and Henk Stunnenberg together with Mihai Netea and other colleagues now show for the first time that even a parasitic infection can train the immune system. The article is published in Frontiers in Molecular Biosciences.read more
Brainy blog Donders Wonders wins prize for science communication3 December 2020
Donders Wonders, the Donders Institute’s science blog, has won the Communication Award of the NWO Domain Science (ENW). The jury praised the bloggers for the impact and reach of the articles they write and called the way the blog is organised ‘an inspiration’.read more
Radboudumc research most lungs recover well after COVID-1926 November 2020
In severe COVID-19 patients the lung tissue recovers well in most cases. This is shown in research by the Radboudumc, published in Clinical Infectious Diseases. Striking conclusion: patients who were referred by the general practitioner recover worse than ICU patients.read more